Nisa Investment Advisors LLC continued to hold its stake in Cambrex Corp. (NYSE:CBM) during the second quarter, Holdings Channel reports. The institutional investor owned 2,100 shares of the company’s stock at the end of the second quarter. Nisa Investment Advisors LLC’s holdings in Cambrex Corp. were worth $109,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in CBM. BlackRock Institutional Trust Company N.A. increased its stake in Cambrex Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 812,239 shares of the company’s stock worth $35,739,000 after buying an additional 2,588 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Cambrex Corp. by 6.1% in the first quarter. Loomis Sayles & Co. L P now owns 428,046 shares of the company’s stock worth $18,834,000 after buying an additional 24,763 shares in the last quarter. Panagora Asset Management Inc. increased its position in Cambrex Corp. by 6.6% in the first quarter. Panagora Asset Management Inc. now owns 372,089 shares of the company’s stock worth $16,372,000 after buying an additional 23,121 shares in the last quarter. Teachers Advisors Inc. increased its position in Cambrex Corp. by 3.9% in the first quarter. Teachers Advisors Inc. now owns 331,966 shares of the company’s stock worth $14,607,000 after buying an additional 12,561 shares in the last quarter. Finally, Royce & Associates LP increased its position in Cambrex Corp. by 0.9% in the first quarter. Royce & Associates LP now owns 203,298 shares of the company’s stock worth $8,945,000 after buying an additional 1,798 shares in the last quarter. Institutional investors own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) traded up 0.88% on Friday, hitting $44.46. 582,725 shares of the stock were exchanged. The stock has a market capitalization of $1.43 billion, a P/E ratio of 22.48 and a beta of 1.45. The company has a 50 day moving average of $45.06 and a 200 day moving average of $47.67. Cambrex Corp. has a one year low of $29.50 and a one year high of $59.41.
Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.09. The business earned $118.22 million during the quarter, compared to the consensus estimate of $114.85 million. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. Cambrex Corp.’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. On average, equities research analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th.
In related news, Director William B. Korb sold 3,420 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the transaction, the director now owns 23,982 shares in the company, valued at $1,319,010. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.63% of the company’s stock.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.